Skip to main content
. Author manuscript; available in PMC: 2010 Sep 2.
Published in final edited form as: Anticancer Drugs. 2010 Aug;21(7):716–723. doi: 10.1097/CAD.0b013e32833cb658

Table 3.

Dose modification levels

Edotecarin (mg/m2) 5-FU (mg/m2)a
46-h infusion
17 Adjustment of edotecarin and 5-FU was made independently based on the specific types of toxicities that were observed 3000a
15 2400
13 2000
11 1600
8
6

5-FU, 5-fluorouracil.

a

In cycle 3 and beyond, the infusional dose of 5-FU could have been increased to 3000 mg/m2 providing that there were no toxicities ≥grade 1 in the preceding cycle.